Purple Biotech’s IM1240, a CAPTN-3-Capped Tri-Specific T- and NK-Cell Engager Targeting 5T4, Shows Robust Tumor Killing in Immunotherapy-Resistant Cancer Models in Plenary Oral Presentation at EORTC-NCI-AACR Symposium

On November 20, 2026 Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, reported the presentation of preclinical data on IM1240, the lead capped tri-specific antibody from its CAPTN-3 platform, in a plenary oral session at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), being held November 18-20, 2026, in Barcelona, Spain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CAPTN-3 is Purple Biotech’s platform of capped tri-specific antibodies. Each antibody combines three arms in a single molecule: a targeting arm that binds a cancer-associated antigen and can be exchanged to address different cancers; a CD3 arm that engages T cells; and an NKG2A arm that engages NK cells and blocks an inhibitory immune checkpoint. The CD3 arm is capped: it is designed to remain inactive in circulation and to be uncapped by proteases in the tumor microenvironment, confining T-cell activation to the cancer and, based on preclinical data, expanding the therapeutic window compared with non-capped T-cell engagers. IM1240, the platform’s lead candidate, targets 5T4.

The findings were presented in a plenary oral session by Amir Horowitz, Ph.D., Associate Professor of Immunology and Immunotherapy and Oncological Sciences at the Icahn School of Medicine at Mount Sinai, and a member of the Marc and Jennifer Lipschultz Precision Immunology Institute and The Tisch Cancer Institute.

"One of the central challenges in cancer immunotherapy is that the presence of cytotoxic immune cells within a tumor does not necessarily translate into effective tumor control. A major blind spot when introducing novel drugs is the assumption that cancer is stagnant in the face of frontline therapies," said Dr. Amir Horowitz. "Our research on the HLA-E/NKG2A pathway has shown how tumors can exploit inhibitory signals to restrain otherwise capable natural killer (NK) cells and T cells. The IM1240 findings provide compelling preclinical evidence for a therapeutic strategy that combines tumor-directed T-cell engagement with relief of NKG2A-mediated immune suppression. The activity observed in treatment-resistant human tumor models is particularly encouraging and warrants further investigation."

"These findings address two key challenges in developing T-cell engagers for solid cancers: immune resistance and systemic immune activation," said Isaac Israel, Interim Chief Executive Officer of Purple Biotech. "Our objective is not simply to recruit more immune cells to cancers, but to enable a more effective anti-tumor response by combining targeted immune engagement with the ability to counteract inhibitory mechanisms within the tumor microenvironment. The contribution of the NKG2A arm in immunotherapy-resistant human cancers, together with the favorable safety and pharmacokinetic profile of our CD3 capping technology, strengthens the scientific foundation as we advance IM1240 toward the clinic."

Presentation Title: Conditionally activated NKG2A-engaging tri-specific antibody remodels IO-resistant human tumor microenvironments with improved tumor killing and pharmacologic safety

Abstract: ENA26-0137
Session: Plenary Session 7 – Proffered Papers: Novel Agents and Targets
Date and Time: Friday, November 20, 2026, 15:24 CET

Addressing immune resistance beyond T-cell recruitment

While T-cell engagers are designed to bring cytotoxic T cells into contact with cancer cells, their activity may remain limited by immunosuppressive mechanisms within the tumor microenvironment. One such mechanism is the HLA-E/NKG2A immune checkpoint: HLA-E, expressed by tumor cells, binds the inhibitory NKG2A receptor on NK cells and subsets of cytotoxic T cells, suppressing their anti-tumor function.

Dr. Horowitz’s work has helped establish the HLA-E/NKG2A pathway as an important regulator of anti-tumor immunity. Recent research from his laboratory, posted as a preprint, found that bladder cancers unresponsive to BCG immunotherapy can retain populations of potentially cytotoxic immune cells while exhibiting increased HLA-E/NKG2A inhibitory interactions. Experimental blockade of NKG2A restored immune-cell function in patient-derived tumor co-cultures, highlighting a potentially actionable mechanism of immune resistance.

These observations reinforce the scientific rationale underlying CAPTN-3: effective anti-tumor immunity may require not only bringing immune cells to cancer cells but also overcoming the inhibitory signals that prevent those immune cells from functioning effectively.

IM1240 integrates three complementary functions within a single antibody: recognition of the tumor-associated antigen 5T4, capped CD3-mediated T-cell redirection, and NKG2A engagement designed to block inhibitory signaling affecting NK cells and cytotoxic T cells. 5T4 is expressed in a variety of solid cancers and is associated with advanced disease and poor clinical outcomes.

NKG2A engagement enhances IM1240’s anti-tumor activity

Data presented at ENA 2026, building on data first presented at the EACR 2026 Annual Congress in June, demonstrated that IM1240 induced anti-tumor activity in patient-derived tumor specimens collected following prior immunotherapy-containing treatment regimens: six head and neck squamous cell carcinoma metastatic lymph node samples, one muscle-invasive bladder cancer resistant to enfortumab vedotin plus pembrolizumab, and one non-small cell lung cancer (NSCLC) tumor resistant to neoadjuvant chemotherapy plus PD-1 blockade. In the dissociated head and neck and bladder specimens, tumor-cell killing required functional CD3 and NKG2A arms; in cancer cell lines, activity depended on 5T4 expression.

In a patient-derived NSCLC explant obtained following chemotherapy and PD-1 inhibitor treatment, IM1240 demonstrated substantially greater anti-tumor activity, achieving an in situ pathologic response score of 94 on a 0–100 scale, compared with 49 for an otherwise comparable antibody with an inactivated NKG2A-binding arm. Similarly, preventing CD3 activation with a non-cleavable cap reduced the response score to 38, highlighting the critical contribution of both functional components to IM1240’s anti-tumor activity.

Spatial imaging of treated NSCLC explants revealed differences in immune-cell distribution and cell-cell interactions between IM1240 and the NKG2A-inactive comparator, suggesting that NKG2A engagement may influence not only direct tumor-cell killing but also the broader immune organization of the tumor microenvironment.

Collectively, these findings provide functional evidence that incorporating NKG2A targeting into a capped T-cell engager can enhance anti-tumor activity beyond CD3-mediated T-cell redirection alone.

CD3 capping supports a favorable safety and pharmacokinetic profile

In addition to its multi-arm immune mechanism, IM1240 incorporates Purple Biotech’s proprietary protease-cleavable CD3 capping technology, designed to restrict full T-cell engagement until the antibody encounters proteolytic conditions associated with the tumor microenvironment.

The ENA presentation also shows that protease-mediated cap removal restores CD3 binding and immune-cell-mediated tumor killing, while a non-cleavable control remains functionally restricted.

Preclinical non-human primate studies further demonstrated that this capping strategy substantially reduced systemic cytokine responses compared with a non-capped antibody, even at higher doses, and prolonged systemic exposure through reduced clearance. As previously reported, IM1240 induced minimal IL-6 and TNF-α at 10 mg/kg, whereas the non-capped variant, IM1222, induced robust cytokine release at just 0.03 mg/kg. IM1240 also showed an approximately 8-fold longer half-life and 16-fold greater systemic exposure.

Together, these findings support a design in which IM1240 circulates with its CD3 arm capped and is activated within the tumor microenvironment, potentially allowing sustained exposure while limiting premature peripheral T-cell activation.

About CAPTN-3

CAPTN-3 is Purple Biotech’s proprietary platform of capped tri-specific antibodies designed to combine tumor-antigen recognition, T-cell engagement, and NKG2A-mediated immune checkpoint modulation. The platform integrates a protease-cleavable CD3 capping mechanism intended to limit systemic T-cell activation while enabling anti-tumor activity within the tumor microenvironment.

(Press release, Purple Biotech, NOV 20, 2026, View Source [SID1234675048])

Boston Scientific announces pricing of $3.0 billion and €4.25 billion offerings of senior notes

On November 20, 2026 Boston Scientific Corporation (the "Company") (NYSE: BSX) reported that it has priced a public offering of $3,000,000,000 aggregate principal amount of U.S. dollar-denominated notes (the "USD Offering"), consisting of $1,000,000,000 aggregate principal amount of 5.375% Senior Notes due 2029, $750,000,000 aggregate principal amount of 5.500% Senior Notes due 2031, $750,000,000 aggregate principal amount of 5.750% Senior Notes due 2033 and $500,000,000 aggregate principal amount of 5.875% Senior Notes due 2036 (collectively, the "USD Notes").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, the Company announced today that American Medical Systems Europe B.V., its indirect wholly owned finance subsidiary, has priced a public offering of €4,250,000,000 aggregate principal amount of euro-denominated notes (the "Euro Offering" and, together with the USD Offering, the "Offerings"), consisting of €500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the "Floating Rate Notes"), €500,000,000 aggregate principal amount of 3.875% Senior Notes due 2028, €750,000,000 aggregate principal amount of 4.125% Senior Notes due 2030, €750,000,000 aggregate principal amount of 4.500% Senior Notes due 2034, €1,000,000,000 aggregate principal amount of 4.750% Senior Notes due 2038 and €750,000,000 aggregate principal amount of 5.125% Senior Notes due 2046 (collectively with the Floating Rate Notes, the "Euro Notes"). The Euro Notes will be fully and unconditionally guaranteed by the Company.

The Offerings are being made pursuant to a registration statement filed with the U.S. Securities and Exchange Commission.

The Offerings are expected to close on December 1, 2026, subject to customary closing conditions. Neither Offering is conditioned upon the completion of the other Offering. The Company intends to use the net proceeds from the Offerings, together with short-term borrowings and/or borrowings under its credit agreement(s) and cash on hand, to finance the cash consideration payable in connection with the acquisition of Penumbra, Inc. (the "Penumbra Acquisition") and to pay related fees and expenses and, to the extent that the net proceeds from the Offerings are not used for such purposes, for general corporate purposes, which may include, among other things, short term investments, reduction of short term debt, funding of working capital and potential future acquisitions.

The Offerings are not conditioned upon the completion of the Penumbra Acquisition. However, if the Penumbra Acquisition is not completed on or before the applicable special mandatory redemption end date, or if the applicable issuer notifies the trustee that the Company will not pursue completion of the Penumbra Acquisition, each series of the USD Notes and the Euro Notes, except for the Floating Rate Notes, will be subject to a special mandatory redemption at a redemption price equal to 101% of the aggregate principal amount of such series, plus accrued and unpaid interest, if any, to, but excluding, the special mandatory redemption date.

Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification under the securities laws of any such state or jurisdiction. The Offerings are being made by means of a prospectus and related separate preliminary prospectus supplements only. Copies of the prospectus and related preliminary prospectus supplement for the USD Notes, and information concerning the USD Offering, may be obtained by contacting the joint book-running managers for the USD Offering: BofA Securities, Inc., toll-free at 1-800-294-1322; Citigroup Global Markets Inc., toll-free at 1-800-831-9146; or J.P. Morgan Securities LLC, collect at 1-212-834-4533. Copies of the prospectus and related preliminary prospectus supplement for the Euro Notes, and information concerning the Euro Offering, may be obtained by contacting the joint book-running managers for the Euro Offering: Barclays Bank PLC, toll-free at 1-888-603-5847; Citigroup Global Markets Europe AG, toll-free at 1-800-831-9146; or J.P. Morgan SE, collect at +49 69 71240 (for non-U.S. investors) or J.P. Morgan Securities LLC collect at 1-212-834-4533 (for U.S. investors).

(Press release, Boston Scientific, NOV 20, 2026, View Source [SID1234675033])

Quanta Presents Class-Leading Monotherapy Data for QTX3034 in KRAS G12D-Mutant Advanced Endometrial Cancer at the EORTC-NCI-AACR Symposium

On November 20, 2026 Quanta Therapeutics, a privately held, clinical-stage biopharmaceutical company leading the development of innovative therapeutics for RAS-driven cancers, reported encouraging clinical data for its oral G12D-preferring multi-KRAS inhibitor QTX3034 in patients with KRAS G12D-mutant endometrial cancer. The late-breaking oral presentation at the EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) (ENA) Symposium 2026 describes data demonstrating substantial and durable anti-tumor activity with QTX3034 monotherapy in a heavily pretreated patient population that had received a median of four prior lines of therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Among 11 patients with KRAS G12D-mutant endometrial cancer treated with QTX3034, the objective response rate (ORR) was 55%, including five partial responses and one complete response. Responses occurred rapidly, with a median time to response of 1.3 months, and were durable, with a median duration of response of 9.7 months. Activity was particularly pronounced among patients with endometrioid histology, the most common subtype of endometrial cancer, where four of five patients, or 80%, achieved an objective response. QTX3034 monotherapy was generally well tolerated, with primarily low-grade adverse events, low rates of dose modification, and no treatment-related adverse events leading to discontinuation.

"These results provide encouraging evidence that direct KRAS inhibition can drive meaningful and durable tumor responses in patients with KRAS G12D-mutant endometrial cancer who have progressed following established therapies," said Judy S. Wang, M.D., Florida Cancer Specialists/Sarah Cannon Research Institute and presenting author of the study. "The depth and durability of the responses are notable in this heavily pretreated population and support further evaluation of QTX3034 in this molecularly defined subset of endometrial cancer."

All 11 patients had mismatch repair-proficient tumors and had previously received chemotherapy and immune checkpoint inhibitor therapy, a clinical setting in which additional treatment options are needed. Seventy-three percent had received at least two prior lines of therapy, 45% had previously received an antibody-drug conjugate, and 36% had received a MAPK-targeting agent.

"We believe these results establish a class-leading clinical signal for QTX3034 in KRAS G12D-mutant endometrial cancer," said Perry Nisen, M.D., Ph.D., Chief Executive Officer of Quanta. "We observed objective responses in more than half of all endometrial cancer patients treated and in four of five patients with endometrioid histology. Together with a tolerable safety profile and high dose intensity, these data strengthen the clinical evidence supporting QTX3034 and provide a clear rationale for further development in KRAS G12D-mutant endometrial cancer."

(Press release, Quanta Therapeutics, NOV 20, 2026, View Source [SID1234675049])

CEL-SCI’s Multikine® Receives Saudi FDA NADR Designation, Accelerating Potential Commercial Launch

On November 20, 2026 CEL-SCI Corporation (NYSE American: CVM) reported that its investigational cancer immunotherapy Multikine (Leukocyte Interleukin, Injection) has been granted official designation under the Saudi Food and Drug Authority’s (SFDA) New Accelerator Program for Drugs in Rare Diseases (NADR). The designation application was successfully submitted by Amarox , CEL-SCI’s in-country regulatory and commercialization partner in Saudi Arabia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The NADR designation positions Saudi Arabia to potentially become the first commercial market globally for Multikine. With NADR status secured, CEL-SCI and Amarox are preparing to submit a Marketing Authorization Application (MAA) to the SFDA within the next 2-3 months. Under recently enacted SFDA guidance, products designated under the NADR pathway qualify for priority review with a target assessment timeframe of 160 working days, supporting a potential commercial launch and initial commercial sales of Multikine in 2027 or early 2028, pending SFDA approval and review of the MAA.

"The Saudi FDA has demonstrated extraordinary global regulatory leadership by establishing the NADR program," stated Geert Kersten, Chief Executive Officer of CEL-SCI. "Their forward-looking framework perfectly aligns with Saudi Vision 2030’s mandate to bring cutting-edge healthcare innovations to the Kingdom rapidly. Because of the SFDA’s proactive approach, we are prioritizing Saudi Arabia as the potential first global commercial market for Multikine. Supported by Amarox’s deep in-country capabilities, we are not only advancing our commercialization strategy but also supporting the Kingdom’s goal of building robust, localized biopharmaceutical infrastructure. This partnership de-risks our commercial transition while delivering on our shared commitment to urgently bring life-extending therapies to head and neck cancer patients. Multikine will initially be supplied from CEL-SCI’s US based manufacturing facility."

"Our partnership with CEL-SCI represents an important step in Saudi Amarox’s strategy to expand into innovative medicines, advanced therapies, and biotechnology," said Dr. Abdullah Alzomaie, Founder and Chief Executive Officer of Saudi Amarox. "We are proud of CEL-SCI’s confidence in Amarox as its regional partner, and we are pleased to see our collaboration achieve an important early milestone through the SFDA’s NADR designation for Multikine. This progress reflects the encouraging environment Saudi Arabia is creating under Vision 2030 to support medical innovation, scientific research, and the introduction of advanced therapies. We see this as the beginning of a promising and long-term partnership."

Accelerated Regulatory Pathway Aligned with Saudi Vision 2030

Launched by the SFDA in August 2026, the NADR program is a cornerstone initiative supporting the healthcare transformation goals of Saudi Vision 2030 and the Kingdom’s National Biotechnology Strategy. NADR is designed to expedite the evaluation of breakthrough therapies that address serious diseases with high unmet medical needs, ensuring Saudi citizens have first-in-class access to advanced medicines. Key benefits of the designation include:

Priority 160-Working-Day Assessment: Eligibility for accelerated review under SFDA submission guidance effective January 1, 2027, establishing a clear pathway for a potential 2027 or early 2028 Multikine launch.
Collaborative Regulatory Framework: Dedicated access to scientific advice and tailored evaluation frameworks, reflecting the SFDA’s commitment to agile, science-based regulation.
Streamlined Access Pathways: Accelerated frameworks designed to bring high-impact immunotherapies to patients rapidly.
Capital-Efficient Commercialization & Local Capability Building

Under the terms of the strategic partnership announced in May 2026, Amarox is CEL-SCI’s local regulatory representative and exclusive commercial distributor for Multikine in Saudi Arabia. Beyond establishing a capital-efficient, 50% / 50% net revenue-sharing model for CEL-SCI, the partnership directly supports Saudi Arabia’s localization goals by utilizing fully funded, in-country marketing, logistics, and sales infrastructure. The agreement also includes an option to expand this localized commercial framework into the broader Gulf Cooperation Council (GCC) member states—including the United Arab Emirates, Kuwait, Qatar, Bahrain, and Oman.

Compelling Phase 3 Clinical Foundation

CEL-SCI intends to seek marketing authorization in Saudi Arabia for the exact target population defined in its planned U.S. registration study: newly diagnosed, previously untreated adult patients with locally advanced, resectable oral cavity squamous cell carcinoma with no lymph node involvement and low/zero tumor PD-L1 expression.

In the world’s largest Phase 3 study for locally advanced head and neck cancer, neoadjuvant treatment with Multikine before standard of care (SOC) delivered dramatic survival benefits in this target population:

73% 5-Year Overall Survival vs. 45% for SOC alone (p = 0.0015).
66% Relative Reduction in Risk of Death compared to SOC alone (Hazard Ratio = 0.34).
Strong Neoadjuvant Mechanism: Administered locally over three weeks immediately following diagnosis, activating an intact immune system prior to surgery, radiation, and chemotherapy.
First Berlin, based in Berlin, Germany, which facilitated the partnership, continues to support CEL-SCI and Amarox as the program moves towards submission and launch in the Kingdom.

About Multikine

Multikine is a novel cancer immunotherapy administered before surgery as a treatment for newly diagnosed previously untreated locally advanced head and neck cancer. It is manufactured at scale, stored in a vial, and injected directly around the tumor. Its goal is to activate a person’s immune system to fight cancer before the ravages of surgery, radiation and chemotherapy have weakened the immune system. In the world’s largest locally advanced head and neck cancer Phase 3 study, Multikine increased the 5-year survival rate of the target patient population to 73% vs 45% in patients treated with standard of care alone and halved the risk of death from 55% to 27%.

(Press release, Cel-Sci, NOV 20, 2026, https://feeds.issuerdirect.com/news-release.html?newsid=7639396368792088&symbol=CVM [SID1234675034])

Leads Biolabs Presents Opamtistomig (PD-L1/4-1BB Bispecific Antibody) to Global Investors at the 2026 Jefferies Global Healthcare Conference

On November 20, 2026 Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) reported the differentiated profile of opamtistomig (LBL-024) to global pharmaceutical companies and investors at the 2026 Jefferies Global Healthcare Conference in London, underscoring the therapy’s global competitiveness in next-generation immuno-oncology (IO 2.0).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Kang Xiaoqiang, the Company’s founder, Chairman and CEO, delivered the invited presentation. He built it around three lines of evidence: the mechanism and clinical evidence behind long-tail survival, activity across tumor types, and safety.

The clinical data support opamtistomig’s potential as a pan-tumor IO 2.0 backbone therapy with durable survival benefit. Results from multiple trials point to activity in settings where conventional immunotherapy has limited reach. Those include low response rates, immunologically "cold" tumors, and tumors with negative or low PD-L1 expression. Deep responses in major indications and a doubling of median overall survival (OS) versus historical data in refractory cold tumors reinforce that positioning. Together, the findings outline five dimensions of value for a next-generation immunotherapy backbone.
(1) Long-term survival potential and managing cancer as a chronic disease: every indication with sufficiently long follow-up — including first-line combination chemotherapy and last-line monotherapy — has shown long-tail survival benefit. Median OS in extrapulmonary neuroendocrine carcinoma (EP-NEC) doubled compared with historical data. In small cell lung cancer (SCLC), median OS remains immature at 18 months of follow-up. Among the first 18 patients with NSCLC, follow-up has passed 12 months and the survival trend is encouraging. With mature follow-up, monotherapy also produced markedly longer OS in later-line biliary tract cancer (BTC), hepatocellular carcinoma (HCC), ovarian cancer (OC) and other cold tumors. The findings suggest advanced cancer may become a chronic disease managed over the long term.
(2) Broad-spectrum efficacy: to date, breakthrough efficacy has been demonstrated in seven tumor types, supporting the potential to become a next-generation broad-spectrum immunotherapy backbone.
(3) Breakthroughs in cold tumors: to date, breakthrough efficacy has been demonstrated in five immunologically cold tumor types, offering the potential to overcome the efficacy limitations of first-generation immunotherapy.
(4) Coverage across patient populations: consistent trends of benefit have been observed in patients with positive, negative and low PD-L1 expression, offering the potential to cover a broader patient population.
(5) Excellent safety: more than 800 patients have received treatment, with no dose-limiting toxicities observed. The overall safety profile is similar to that of PD-(L)1 monoclonal antibodies, supporting long-term administration in broader patient populations.

At the conference, Leads Biolabs disclosed for the first time plans to launch several ADC combination programs in 2027. The programs include combinations with its in-house next-generation bispecific ADCs and T-cell engager ADCs (TCE-ADCs), as well as with ADCs from leading industry players.

Long-Tail Survival: A Mechanism Built on Long-Lived Memory T Cells

Opamtistomig is built with high affinity for PD-L1 and very low affinity for 4-1BB. The design enables conditional 4-1BB activation in the tumor microenvironment. Checkpoint blockade and co-stimulation therefore occur only within the tumor microenvironment. While avoiding hepatotoxicity caused by 4-1BB activation in normal tissues, this design reshapes the immunosuppressive tumor microenvironment. It significantly promotes T-cell activation and proliferation, stimulates abundant cytokine secretion and substantially reduces the number of regulatory T cells. Most importantly, it generates long-lived memory T cells. Those cells continue immune surveillance after treatment stops, which is the fundamental basis for opamtistomig’s ability to overcome the limitations of conventional immunotherapy and deliver durable survival benefits to patients.

Clinical Data: Median OS Doubled in EP-NEC, with Long-Tail Trends in SCLC and Three Other Tumor Types

EP-NEC is the indication with the most mature survival data for opamtistomig. Long-term survival data have been reported from both first-line and heavily pretreated studies (2026 ESMO (Free ESMO Whitepaper) late-breaking abstract and selected oral presentation data).

In the pivotal registrational study of opamtistomig monotherapy in third-line or later EP-NEC (n=96), median follow-up was 16.3 months. Median OS was 8.7 months, versus approximately 3-4 months in historical data.

In first-line EP-NEC with combination chemotherapy (n=69), median follow-up was 21.2 months. Median OS was immature, and the 18-month OS rate was 55.7%. Historical median OS with first-line chemotherapy was 11.5-12.5 months.

In small cell lung cancer (SCLC), median follow-up has reached 18 months. OS data remain immature, and the long-term survival trend is encouraging. In monotherapy cohorts of heavily pretreated patients from an early basket trial, follow-up has passed two years and OS data are mature. All three tumor types showed encouraging long-tail benefit trends.

In third-line or later biliary tract cancer (BTC) (n=31), median OS was 7.5 months as a third-line or later treatment, numerically exceeding historical second-line data of 6.2 months with mFOLFOX and 5.3 months with regorafenib. In hepatocellular carcinoma (HCC) previously treated with immunotherapy (n=14), median OS was 13.3 months. Historical second-line data were 10.6 months with regorafenib and 10.2 months with cabozantinib. In second-line or later ovarian cancer (OC) (n=11), median OS was 26.5 months. Historical second-line data with bevacizumab plus chemotherapy were 13.3 months.

The conference also included updated follow-up for the first 18 patients with non-small cell lung cancer (NSCLC). Follow-up reached 12.3 months, and responses continued to deepen. The data also point to long-tail potential.

All subtypes showed responses lasting longer than historical median progression-free survival (PFS) for standard treatment in the same indication. Every patient still on treatment had maintained a response for about 12 months. Historical median PFS was approximately 3-4 months in immunotherapy-pretreated non-squamous NSCLC, 8-9 months in first-line non-squamous NSCLC and about 7 months in first-line squamous NSCLC.

Prolonged responses were seen in PD-L1-positive and squamous populations. Two PD-L1-positive patients with first-line non-squamous disease and five patients with first-line squamous disease had each remained on treatment for more than 357 days. All were still on treatment. The Company views these durations as a meaningful survival signal and sees competitive potential against other bispecific antibodies.

Many patients remained in response at longer follow-up. The Company had presented these 18 patients at the 2026 World Conference on Lung Cancer (WCLC), when median follow-up was about 10 months. Compared with that update, nine patients remained on treatment at the longer follow-up and only two additional progressions were recorded. That pattern is consistent with the course of cancer treatment.

Broad Activity: Responses in Seven Tumor Types and Six Oral Presentations at Major Congresses

Responses have been observed repeatedly in seven indications, including the major indication of NSCLC and five immunologically "cold" tumor types. Studies have been selected six times for oral presentations at leading international oncology congresses, including the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) and the World Conference on Lung Cancer (WCLC).

First-Line NSCLC (2026 WCLC Oral Presentation Data)
In the squamous cohort (n=31), median follow-up was 7.4 months. The objective response rate (ORR) was 87.1% and the disease control rate (DCR) was 96.8%. The six-month PFS rate reached 86.7%. Patients with positive and negative PD-L1 expression showed consistent benefit trends. ORRs were 84.6% and 88.2%, respectively. Six-month PFS rates were 84.6% and 87.4%, respectively.

In the non-squamous cohort (n=31), median follow-up was 6.9 months. ORR was 54.8% and DCR was 93.5%. In the PD-L1-positive subgroup, ORR reached 81.8% and DCR reached 100.0%. The six-month PFS rate reached 90.0%. Responses were also seen in patients with low PD-L1 expression, with a tumor proportion score of 1%-49%.

First-Line BTC (2026 ESMO (Free ESMO Whitepaper) Poster Data)
In the overall population (n=20), median follow-up was 8.6 months. ORR was 70.0% and DCR was 95%. Median PFS was 8.0 months, and the six-month OS rate was 90.0%. In the PD-L1-positive subgroup, ORR was 100.0% and the six-month OS rate was 100.0%. In the PD-L1-negative subgroup, ORR was 50.0% and DCR was 91.7%. Median PFS was 7.2 months, and the six-month OS rate was 83.3%.

First-Line HCC
Data were updated with a larger sample and longer follow-up than the 2026 interim results disclosure. In the overall population (n=23), median follow-up was approximately seven months. ORR was 43.5% and DCR was 82.6%. In the PD-L1-positive subgroup, ORR was 50% and DCR was 75%. The subgroup grew from five to 12 patients since the 2026 interim results, with the response level holding steady.

First-Line Esophageal Squamous Cell Carcinoma (ESCC)
Data were updated with longer follow-up than the 2026 interim results disclosure. In the overall population (n=20), median follow-up was approximately 5.5 months. ORR was 70% and DCR was 90%. In the PD-L1-positive subgroup, ORR was 77.8% and DCR was 100%.

Platinum-Resistant OC
In the overall population (n=12), median follow-up was approximately 2.5 months. ORR was 16.7% and DCR was 66.7%. Neither median PFS nor median OS had been reached. In the PD-L1-positive subgroup, ORR was 40% and DCR was 80%. Neither median PFS nor median OS had been reached.

First-Line SCLC
ORR was 88.1% and DCR was 96.6%. As of October 2026, median follow-up was 18 months and OS data remained immature.

EP-NEC
Data from multiple clinical studies of monotherapy in previously treated EP-NEC demonstrated consistent benefits across lines of therapy. In second-line, second-line or later, and third-line or later settings, ORRs were 38.1%, 33.3% and 26.0%, respectively. Median PFS was 4.1, 2.8 and 1.4 months, respectively. Median OS was 11.8, 11.9 and 8.7 months, respectively.

In first-line EP-NEC with combination chemotherapy, ORR was 69.2% and DCR was 90.8%. Median PFS was 5.7 months. Median OS was immature, and the 18-month OS rate was 55.7%.

Safety: More Than 800 Patients Treated With No Dose-Limiting Toxicities

Hepatotoxicity has long limited the clinical use of 4-1BB agonists. Opamtistomig’s conditional 4-1BB activation is designed to address that challenge at the mechanistic level. To date, more than 800 patients have received opamtistomig across 14 indications. No dose-limiting toxicities have been observed. The maximum tolerated dose was not reached even with dose escalation to 25 mg/kg. Safety and tolerability were similar across monotherapy and combination trials. The overall safety profile was similar to that of PD-(L)1 monoclonal antibodies. Those findings support longer-term dosing in broader populations and further study of combination regimens.

Building on the responses seen with opamtistomig plus chemotherapy in cold tumors, the Company plans to test combinations with antibody-drug conjugates (ADCs). The approach retains the targeted cytotoxic effect of ADCs while using the immune system to clear tumor cells. The goal is a next-generation standard of care. Combinations under consideration include opamtistomig with an EGFR/PD-L1 ADC, a CDH17/CD3/ADC and a DLL3/CD3/ADC, as well as several ADCs from leading industry players. Beyond ADC combinations, the Company also plans to explore regimens with other molecules, including anti-VEGF agents and T-cell engagers (TCEs), to establish new standards of care in specific tumor types.

During the conference, the Company’s senior management held a series of closed-door, one-on-one business development and investor meetings. Discussions with overseas institutions covered registration timelines by indication, global clinical development plans, commercialization strategy and pipeline synergies.

Executive Commentary

"Taking part in Jefferies was about more than sharing clinical data," said Dr. Kang Xiaoqiang, founder, Chairman and CEO of Leads Biolabs. "It let us present the full logic behind our differentiated innovation to global investors and industry partners. It also helped advance our global registration plans and international partnerships.

"Cancer immunotherapy has entered the IO 2.0 era. Opamtistomig’s value lies in a manageable safety profile and the potential for long overall survival benefit across tumor types. Together, those features offer a new treatment framework in areas that conventional immunotherapy has struggled to reach."

About the Jefferies Global Healthcare Conference
Hosted by U.S. investment bank Jefferies, the Jefferies Global Healthcare Conference is one of the world’s largest healthcare investment summits. The 2026 invitation-only meeting took place Nov. 16-19 at The Waldorf Hilton, London and ME London, alongside London Life Sciences Week. The conference covers biotechnology, pharmaceuticals, medical devices and healthcare services. Company presentations, one-to-one and small-group investor meetings, and panel discussions focus on near- and longer-term investment opportunities and industry trends in global healthcare.

About Opamtistomig
Opamtistomig (LBL-024) is emerging as a next-generation pan-cancer backbone therapy with potential overall survival (OS) benefit that simultaneously targets PD-L1 and the co-stimulatory receptor 4-1BB. Currently, opamtistomig is being evaluated in 14 indications, including one pivotal single-arm registrational study, one confirmatory Phase III study, and nine proof-of-concept studies, covering major indications such as NSCLC and multiple cold tumors. To date, opamtistomig has demonstrated robust antitumor activity across seven tumor types—extrapulmonary neuroendocrine carcinoma (EP-NEC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), biliary tract cancer (BTC), hepatocellular carcinoma (HCC), esophageal squamous cell carcinoma (ESCC), and ovarian cancer (OC)—highlighting its clinical value and broad therapeutic promise.

Developed using Leads Biolabs’ proprietary X-body bispecific platform, opamtistomig is designed to simultaneously block PD-1/PD-L1 immune suppression and conditionally activate 4-1BB, an agonist pathway, resulting in a potent and synergistic anti-tumor immune response. It has a safety profile comparable to PD-1/PD-L1 inhibitors and demonstrates broader-spectrum anti-cancer potential. Mechanistically, 4-1BB agonism can reactivate exhausted T cells and promote robust T-cell proliferation, offering significant promise for PD-1/PD-L1–resistant or immunologically "cold" tumors and potentially offering durable survival benefits.

Recognizing its clinical potential in EP-NEC, opamtistomig received Breakthrough Therapy Designation from China’s National Medical Products Administration (NMPA) in October 2024, Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) in November 2024, Fast Track Designation from the FDA and ODD from the European Commission in January 2026, and ODD from Japan’s Ministry of Health, Labour and Welfare (MHLW) in September 2026. In October 2026, the FDA granted a second Fast Track Designation, this one for first-line advanced or metastatic biliary tract cancer.

In July 2026, its New Drug Application (NDA) was granted priority review designation by the NMPA, followed by NDA acceptance in August 2026, positioning opamtistomig as a potential world’s first approved 4-1BB-targeting antibody, the first approved agonist antibody, and the first approved treatment for EP-NEC.

(Press release, Nanjing Leads Biolabs, NOV 20, 2026, View Source [SID1234675050])